Abstracts tagged "Pediatric rheumatology"

Abstract Number: 1767 • ACR Convergence 2024
Endothelial Cell-Driven JAG/NOTCH Signaling in Localized Scleroderma Patients
Theresa Hutchins¹, Anwesha Sanyal¹, Deren Esencan¹ and Kathryn Torok², ¹University of Pittsburgh, Pittsburgh, PA, ²Division of Rheumatology, Scleroderma Center, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA
Background/Purpose: Localized scleroderma is a rare autoimmune disease primarily affecting the skin and underlying tissue. While its exact pathogenesis remains unclear, studies suggest links to…
Abstract Number: 1926 • ACR Convergence 2024
Race/ethnicity Is Associated with Disease Severity in Pediatric Patients with ANCA-associated Vasculitis Hospitalized in the United States
Rob Valdovinos¹, William Soulsby² and Emily von Scheven², ¹UCSF Benioff Children's Hospital, San Francisco, CA, ²University of California, San Francisco, San Francisco, CA
Background/Purpose: Race and ethnicity are societal constructs that contribute to health disparities. Small studies have found that Hispanic patients with ANCA-associated vasculitis (AAV) are more…
Abstract Number: 2188 • ACR Convergence 2024
Parent Verses Patient Perspectives of Health-Related Quality of Life Among Children with Vasculitis
Clare Peckenpaugh¹, Aimee Hersh², Sara Stern², Erin Treemarcki², Peter Merkel³ and Karen James², ¹University of Utah Department of Pediatrics, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Vasculitis is a group of chronic, relapsing diseases that can lead to significant morbidity due to both disease and treatment, impacting patients’ health related…
Abstract Number: 2206 • ACR Convergence 2024
There Is No Difference in Major Organ Involvement Andantibody Pattern Between Diffuse and Limited Subtypejuvenile Onsetsystemic Scleroderma Patients
Ivan Foeldvari¹, Jens Klotsche², Kathryn Torok³, Ozgur Kasapcopur⁴, Amra Adrovic⁵, Brian Feldman⁶, Flavio Sztajnbok⁷, Jordi Anton⁸, Sindhu R. Johnson⁹, Maria Teresa Terreri¹⁰, Ana Sakamoto¹¹, Raju Khubchandani¹², Valda Stanevica¹³, Gülcan Özomay Baykal¹⁴, Dieneke Schonenberg-Meinema¹⁵, Eslam Al-Abadi¹⁶, Ekaterina Alexeeva¹⁷, Maria Katsicas¹⁸, Sujata Sawhney¹⁹, vanessa smith²⁰, Simone Appenzeller²¹, Tadey Avcin²², Mikhail Kostik²³, Thomas Lehman²⁴, Suzanne Li²⁵, Hana Malcova²⁶, edoardo marrani²⁷, Clare Pain²⁸, Anjali Patwardhan²⁹, Walter Alberto Sifuentes-Giraldo³⁰, Natalia Vasquez-Canizares³¹, Sima Abu Alsaoud³², Patricia Costa Reis³³, Hajek, Stefanie Hajek, Stefanie³⁴, Mahesh Janarthanan³⁵, Dana Nemcova³⁶, Siri Opsahl Hetlevik³⁷, Maria Jose Santos³⁸, Cristina Battagliotti³⁹, Lillemor Berntson⁴⁰, blanca e r bica⁴¹, Jürgen Brunner⁴², Liora Harel⁴³, Gerd Horneff⁴⁴, Daniela Kaiser⁴⁵, Dragana Lazarevic⁴⁶, Farzana Nuruzzaman⁴⁷, Mihaela Sparchez⁴⁸ and Nicola Helmus¹, ¹Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Division of Rheumatology, Scleroderma Center, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, ⁴Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey, ⁵Cerrahpasa Medical School, Istanbul, Turkey, ⁶Division of Rheumatology, The Hospital for Sick Children; Departments of Pediatrics and Medicine, Faculty of Medicine; The Institute for Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ⁷UFRJ/UERJ, SAO PAULO, Brazil, ⁸Hospital Sant Joan de Déu. Universitat de Barcelona, Esplugues de Llobregat (Barcelona), Spain, ⁹University of Toronto, Toronto, Canada, ¹⁰UNIFESP, São Paulo, SP, Brazil, ¹¹Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil, ¹²SRCC Childrens Hospital, Mumbai, India, ¹³Childrens Clinical University Hospital, Zemgales priekšpilseta, Riga, Latvia, ¹⁴Umraniye Training and Research Hospital, Istanbul, Turkey, ¹⁵Emma Children’s Hospital, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, ¹⁶Birmingham Women’s and Children’s Hospital NHSFT, Birmingham, United Kingdom, ¹⁷National Medical Research Center of Children's Health, Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia, ¹⁸Hospital Garrahan, Buenos Aires, Argentina, ¹⁹Sir Ganga Ram Hospital, Sector 37 noida, Uttar Pradesh, India, ²⁰Ghent University Hospital, Gent, Belgium, ²¹Unicamp, Campinas, SP, Brazil, ²²University Children's Hospital University Medical Center Ljubljana, Ljubljana, Slovenia, ²³Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ²⁴Hospital for Special Surgery, New York, NY, ²⁵Hackensack University Medical Center, Hackensack, ²⁶Motol University Hospital, Prague, Czech Republic, ²⁷Dipartimento Neurofarba, Università di Firenze, Firenze, Italy, ²⁸Alderhey Children's NHS Foundation Trust, Liverpool, United Kingdom, ²⁹University of Missouri-Columbia, Department of Child Health, 404 N Keene Street, Columbia MO 65210, Columbia, ³⁰Hospital Universitario Ramon y Cajal, Madrid, Spain, ³¹Children’s Hospital at Montefiore, Bronx, NY, ³²Caritas baby Hospital, East Jerusalem, Israel, ³³Hospital de Santa Maria, Lisbon, Portugal, ³⁴Deutsches Zentrum für Kinder- und Jugendrheumatologie, Garmisch-Partenkirchen, Germany, ³⁵SRI RAMACHANDRA INSTITUTE OF HIGHER EDUCATION AND RESEARCH, Chennai, Tamil Nadu, India, ³⁶MD, Prague, Czech Republic, ³⁷Oslo University Hospital, Oslo, Norway, ³⁸Hospital Garcia de Orta and Centro Académico de Medicina de Lisboa, Lisboa, Portugal, ³⁹Hospital de Niños Dr Orlando Alassia, Santa Fe, Argentina, ⁴⁰Dept. of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden, ⁴¹UNIVERSIDADE FEDERAL DO RIO DE JANEIRO, Rio de Janeiro, Brazil, ⁴²Medical University Innsbruck; Department of Pediatrics, Pediatric Rheumatology, Innsbruck, Austria, ⁴³Faculty of Medicine, Tel Aviv University, Tel Aviv; Pediatric Rheumatology Unit, Schneider Children's Medical Center of Israel, Petach Tikva, Israel, Petach Tikva, HaMerkaz, Israel, ⁴⁴Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ⁴⁵Childrens Hospital Lucerne, Lucerne, Switzerland, ⁴⁶Dept of Pediatric Rheumatology and Immunology Clinical Center Nis, Faculty of Medicine, University of Niš, Nis, Serbia, ⁴⁷Stony Brook Children's Hospital, Stony Brook, NY, ⁴⁸Emergency Clinical Hospital for Children, Cluj-Napoca, Romania
Background/Purpose: In adult systemic sclerosis they are significant differences in clinical presentation of diffuse and limited subtype. In juvenile systemic sclerosis (jSSc) are the differences less…
Abstract Number: 2623 • ACR Convergence 2024
Cardiovascular Health Is Suboptimal in Most Patients with Juvenile-Onset Lupus and Dermatomyositis: Baseline Visit Findings from the Lupus Erythematous and Dermatomyositis Stress and Cardiovascular Health Cohort Study
Kaveh Ardalan¹, Angel Davalos², Hwanhee Hong², Bryce Reeve², Christoph Hornik², M. Athony Moody², Donald Lloyd-Jones³, Eveline Wu⁴, Audrey Ward¹, Rebecca Sadun⁵, Jeff Dvergsten⁶, Ann Reed², Mark Connelly⁷ and Laura Schanberg⁸, ¹Duke University School of Medicine, Durham, NC, ²Duke University School of Medicine, Durham, ³Northwestern University Feinberg School of Medicine, Chicago, ⁴University of North Carolina School of Medicine, Chapel Hill, NC, ⁵Duke University, Durham, NC, ⁶Duke University Hospital, Hillsborough, NC, ⁷Children’s Mercy Kansas City/University of Missouri-Kansas City School of Medicine, Kansas City, ⁸Duke University Medical Center, DURHAM, NC
Background/Purpose: Juvenile lupus (JSLE) and dermatomyositis (JDM) are associated with premature cardiovascular disease (CVD). The American Heart Association (AHA) cardiovascular health (CVH) score is the…
Abstract Number: 0186 • ACR Convergence 2024
Development of a Novel Dried Blood Spot Method to Improve Capacity for ANA Testing in Lower-Resource Settings
Ekemini Ogbu¹, Stela Florea², Donna Diorio², Somak Roy², Dhriti Sharma², Michael Henrickson², Patricia Vega-Fernandez², Angela Migowa³, Sarangarajan Ranganathan² and hermine brunner¹, ¹Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³AGA KHAN UNIVERSITY, Nairobi, Kenya
Background/Purpose: Timely diagnosis of children and young adults with rheumatologic disorders remains a global challenge especially in lower-resource settings. There is limited access to diagnostic…
Abstract Number: 0397 • ACR Convergence 2024
Trends in New Use of Disease-Modifying Antirheumatic Drugs in Juvenile Idiopathic Arthritis Among Commercially Insured Children in the United States from 2001-2022
Priyanka Yalamanchili¹, Lydia Lee², Greta Bushnell³, Melissa Mannion⁴, Chintan Dave⁵ and Daniel B. Horton⁶, ¹Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy, and Aging Research, Morris Plains, NJ, ²Center for Health Outcomes, Policy & Economics, Rutgers Ernest Mario School of Pharmacy and Rutgers School of Public Health, Piscataway, NJ, ³Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy, and Aging Research; Department of Biostatistics and Epidemiology, Rutgers School of Public Health, New Brunswick, NJ, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy, and Aging Research; Center for Health Outcomes, Policy & Economics, Rutgers Ernest Mario School of Pharmacy and Rutgers School of Public Health, New Brunswick, NJ, ⁶Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy, and Aging Research; Department of Biostatistics and Epidemiology, Rutgers School of Public Health; Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disorder. An increasing array of disease-modifying antirheumatic drugs (DMARDs) have become available to treat…
Abstract Number: 0832 • ACR Convergence 2024
Spatial Transcriptomic Assessment of Histologically Damaged and Unaffected Glomeruli in Class III Pediatric Lupus Nephritis Reveals Distinct Transcriptional Programs
Sarah McCuaig¹, Portia Kreiger¹ and Edward Behrens², ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, West Chester, PA
Background/Purpose: Lupus nephritis (LN) occurs in over 50% of patients with pediatric systemic lupus erythematosus (pSLE) and results in significant morbidity due to suboptimal kidney…
Abstract Number: 1265 • ACR Convergence 2024
Approach to Janus Kinase Inhibition for Juvenile Dermatomyositis Among Childhood Arthritis and Rheumatology Research Alliance (CARRA) and Paediatric Rheumatology European Society (PReS) Providers
Emily Datyner¹, Rebecca Nicolai², Silvia Rosina³, Angela Hamilton⁴, Kaveh Ardalan⁵, Brigitte Bader-Meunier⁶, Amanda Brown⁷, Raquel Campanilho-Marques⁸, Marc Jansen⁹, Susan Kim¹⁰, Bianca Lang¹¹, Liza McCann¹², Helga Sanner¹³, Meredyth Wilkinson¹⁴, Belina Yi¹⁵, Hanna Kim¹⁶, Matthew Sherman¹⁷, Stacey Tarvin⁴ and Charalampia Papadopoulou¹⁸, and the CARRA and PReS investigators, ¹Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN, ²Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ³IRCCS Istituto Giannina Gaslini, Genoa, Italy, ⁴Indiana University School of Medicine, Indianapolis, IN, ⁵Duke University School of Medicine, Durham, NC, ⁶Necker Hospital, Assistance Publique Hopitaux de Paris, Paris, France, ⁷University of Arkansas for Medical Sciences, Little Rock, AR, ⁸Lisbon Academic Medical Centre, Lisboa, Portugal, ⁹University Medical Center Utrecht, Utrecht, Netherlands, ¹⁰University of California, San Francisco, CA, ¹¹Dalhousie University and IWK Health, Halifax, NS, Canada, ¹²Alder Hey Children's NHS Foundation Trust, Liverpool, England, United Kingdom, ¹³Oslo University Hospital, Oslo, Norway, ¹⁴Great Ormond Street Institute of Child Health, London, United Kingdom, ¹⁵Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁶National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ¹⁷DAIT/NIAID/NIH, Washington, DC, ¹⁸Great Ormond Street Hospital for Children, NHS Foundation Trust, London, United Kingdom
Background/Purpose: Janus kinase inhibitors (JAKi) have been proposed as a treatment for idiopathic inflammatory myopathies to target increased interferon signaling. Predominantly retrospective reports have demonstrated…
Abstract Number: 1283 • ACR Convergence 2024
Acute Transverse Myelitis in Pediatric Systemic Lupus Erythematosus
Meredith Rae¹, Emily Beil², Juan Carlos Torres², Kristen Fisher² and Eyal Muscal³, ¹Baylor College of Medicine/Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine/Texas Children's Hospital, Houston, ³Baylor College of Medicine, Houston, TX
Background/Purpose: Transverse myelitis (TM) has an incidence of 1-2% in pediatric SLE and is often a feature of early disease. Most patients ( >60%) have…
Abstract Number: 1769 • ACR Convergence 2024
Top Peripheral Blood Transcriptomic Gene Modules Reveal Functional Annotation and Correlation with Clinical Traits in Juvenile Dermatomyositis (JDM) and Myositis-Specific Autoantibody (MSA) Groups
Ujana Zajmi¹, Megan Darrell¹, Amy Kaneshiro¹, Adeline Chin¹, Adriana Jesus², Stephen Brooks¹, Raphaela Goldbach-Mansky², Lisa Rider³ and Hanna Kim⁴, ¹NIH/NIAMS, Bethesda, MD, ²NIH/NIAD, Bethesda, MD, ³NIEHS, NIH, Garrett Park, MD, ⁴National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Myositis-specific autoantibody (MSA) subgroups define phenotypes associated with specific clinical traits and outcomes within JDM, a clinically heterogeneous autoimmune disease. The pathogenesis of JDM…
Abstract Number: 1932 • ACR Convergence 2024
Effects of Clinical Decision Support on Transition Readiness Assessment in Pediatric Rheumatology
Chrisana Pokorny¹ and Bethany Marston², ¹University of Rochester, Webster, NY, ²University of Rochester, Rochester, NY
Background/Purpose: Pediatric to adult transition is often challenging among young adults with rheumatic diseases. Structured transition programs can improve adherence to care, quality of life,…
Abstract Number: 2189 • ACR Convergence 2024
Migratory Arthritis in Children: What Besides Rheumatic Fever?
bar goldberg¹, Gil Amarilyo², oded Scheuerman¹, tarek Zuabi³, alina Guz¹, Maayan Ravia¹ and yoel Levinsky¹, ¹schneider medical center, petah tikva, Israel, ²Faculty of Medicine, Tel Aviv University, Tel Aviv; Pediatric Rheumatology Unit, Schneider Children's Medical Center of Israel, Petach Tikva, Israel, Kibbutz Maggal, HaMerkaz, Israel, ³schneider medical center, petah tikva
Background/Purpose: Migratory Arthritis, a not uncommon presentation in pediatrics, is classically associated with rheumatic fever (RF), although can be the first presentation of other medical…
Abstract Number: 2207 • ACR Convergence 2024
Improvement Across Physician and Patient Reported Outcome Measures over a 24 Months-time Period in the Juvenile Systemic Scleroderma Inception Cohort
Ivan Foeldvari¹, Jens Klotsche², Ozgur Kasapcopur³, Amra Adrovic⁴, Kathryn Torok⁵, Maria Teresa Terreri⁶, Ana Sakamoto⁷, Jordi Anton⁸, Brian Feldman⁹, Raju Khubchandani¹⁰, Tadey Avcin¹¹, Sindhu R. Johnson¹², Mikhail Kostik¹³, Edoardo Marrani¹⁴, Flavio Sztajnbok¹⁵, Maria Katsicas¹⁶, Dana Nemcova¹⁷, Maria Jose Santos¹⁸, Simone Appenzeller¹⁹, Cristina Battagliotti²⁰, Lillemor Berntson²¹, Jürgen Brunner²², Liora Harel²³, Gerd Horneff²⁴, Tilmann Kallinich²⁵, Kirsten Minden², Farzana Nuruzzaman²⁶, Anjali Patwardhan²⁷, Dieneke Schonenberg-Meinema²⁸ and Nicola Helmus²⁹, ¹Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey, ⁴Cerrahpasa Medical School, Istanbul, Turkey, ⁵Division of Rheumatology, Scleroderma Center, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, ⁶UNIFESP, São Paulo, SP, Brazil, ⁷Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil, ⁸Hospital Sant Joan de Déu. Universitat de Barcelona, Esplugues de Llobregat (Barcelona), Spain, ⁹Division of Rheumatology, The Hospital for Sick Children; Departments of Pediatrics and Medicine, Faculty of Medicine; The Institute for Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ¹⁰SRCC Childrens Hospital, Mumbai, India, ¹¹University Children's Hospital University Medical Center Ljubljana, Ljubljana, Slovenia, ¹²University of Toronto, Toronto, Canada, ¹³Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ¹⁴University of Florence, Firenze, Florence, Italy, ¹⁵UFRJ/UERJ, SAO PAULO, Brazil, ¹⁶Hospital Garrahan, Buenos Aires, Argentina, ¹⁷MD, Prague, Czech Republic, ¹⁸Hospital Garcia de Orta and Centro Académico de Medicina de Lisboa, Lisboa, Portugal, ¹⁹Unicamp, Campinas, SP, Brazil, ²⁰Hospital de Niños Dr Orlando Alassia, Santa Fe, Argentina, ²¹Dept. of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden, ²²Medical University Innsbruck; Department of Pediatrics, Pediatric Rheumatology, Innsbruck, Austria, ²³Faculty of Medicine, Tel Aviv University, Tel Aviv; Pediatric Rheumatology Unit, Schneider Children's Medical Center of Israel, Petach Tikva, Israel, Petach Tikva, HaMerkaz, Israel, ²⁴Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ²⁵Charite, Berlin, Germany, ²⁶Stony Brook Children's Hospital, Stony Brook, NY, ²⁷University of Missouri-Columbia, Department of Child Health, 404 N Keene Street, Columbia MO 65210, Columbia, ²⁸Emma Children’s Hospital, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, ²⁹Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany
Background/Purpose: Juvenile systemic sclerosis (jSSc) is an orphan disease with a prevalence of 3 in 1 000 000 children. The Juvenile Systemic Scleroderma Inception cohort…
Abstract Number: 2624 • ACR Convergence 2024
Measuring Clinically Inactive Disease at One Year in Patients with Juvenile Dermatomyositis (JDM) in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Jessica Neely¹, Peter Shrader², Stacey Tarvin³, Kaveh Ardalan⁴, Susan Shenoi⁵, Adam Huber⁶, Susan Kim⁷ and Hanna Kim⁸, and for the CARRA Registry Investigators, ¹UCSF, San Francisco, CA, ²Duke Clinical Research Institute, Durham, NC, ³Indiana University School of Medicine, Indianapolis, IN, ⁴Duke University School of Medicine, Durham, NC, ⁵Seattle Children's Hospital and Research Center, Mercer Island, WA, WA, ⁶IWK Health Centre, Halifax, NS, Canada, ⁷University of California, San Francisco, CA, ⁸National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: While remission off medication is the goal in JDM, timely achievement of clinically inactive disease (CID) is an important interim outcome. Data from the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].